Auris, nasus, larynx · 2015
Management for squamous cell carcinoma of the nasal cavity and ethmoid sinus: A single institution experience.
Clinical StudyСтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Homma Akihiro, Nakamaru Yuji, Sakashita Tomohiro, Onimaru Rikiya, Terasaka Shunsuke, Tsuchiya Kazuhiko, Yoshida Daisuke, Yasuda Koichi, Hatakeyama Hiromitsu, Furusawa Jun, Mizumachi Takatsugu, Kano Satoshi, Shirato Hiroki, Fukuda Satoshi
Аннотация
OBJECTIVE: Here we report our experience of patients with squamous cell carcinoma (SCC) of the nasal cavity and ethmoid sinus (NC&ES) together with an analysis of treatment outcomes.
METHODS: A retrospective analysis was performed using data from 25 consecutive patients treated between 2000 and 2012. Four patients were diagnosed with T1, 3 with T2, 4 with T3, 7 with T4a, and 7 with T4b disease. No patient had lymph node metastasis.
RESULTS: Twelve patients were treated with surgery with/without radiotherapy and with/without chemotherapy. Of these, 4 underwent endoscopic surgery without an open approach and 3 required an anterior skull base approach. Thirteen were treated with radiotherapy; 1 with radiotherapy alone, and 4 and 8 with intravenous and intra-arterial chemotherapy, respectively. The 5-yr overall survival for T1-3, T4a, and T4b disease was 53.9%, 71.4%, and 29.0%, respectively. The 5-yr disease-specific survival for T1-3, T4a, and T4b disease was 74.1%, 71.4%, and 29.0%, respectively.
CONCLUSION: Our treatment policy for patients with SCC of NC&ES, which basically follows the NCCN guideline, was considered to be appropriate. However, several points in terms of surgery and non-surgical approach remain to be solved through further research.
METHODS: A retrospective analysis was performed using data from 25 consecutive patients treated between 2000 and 2012. Four patients were diagnosed with T1, 3 with T2, 4 with T3, 7 with T4a, and 7 with T4b disease. No patient had lymph node metastasis.
RESULTS: Twelve patients were treated with surgery with/without radiotherapy and with/without chemotherapy. Of these, 4 underwent endoscopic surgery without an open approach and 3 required an anterior skull base approach. Thirteen were treated with radiotherapy; 1 with radiotherapy alone, and 4 and 8 with intravenous and intra-arterial chemotherapy, respectively. The 5-yr overall survival for T1-3, T4a, and T4b disease was 53.9%, 71.4%, and 29.0%, respectively. The 5-yr disease-specific survival for T1-3, T4a, and T4b disease was 74.1%, 71.4%, and 29.0%, respectively.
CONCLUSION: Our treatment policy for patients with SCC of NC&ES, which basically follows the NCCN guideline, was considered to be appropriate. However, several points in terms of surgery and non-surgical approach remain to be solved through further research.
Предметные рубрики MeSH
AdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsCarboplatinCarcinoma, Squamous CellChemoradiotherapy, AdjuvantCisplatinCohort StudiesDocetaxelEndoscopyEthmoid SinusFemaleFluorouracilHead and Neck NeoplasmsHumansInfusions, Intra-ArterialMaleMiddle AgedNasal CavityNeoplasm StagingNose NeoplasmsOrganoplatinum CompoundsOtorhinolaryngologic Surgical ProceduresParanasal Sinus NeoplasmsRadiotherapy, AdjuvantRetrospective StudiesSquamous Cell Carcinoma of Head and NeckTaxoids